Coherus Oncology (CHRS) Revenue (2013 - 2026)

Coherus Oncology (CHRS) has 13 years of Revenue data on file, last reported at $12.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 61.99% year-over-year to $12.3 million; the trailing twelve-month figure through Mar 2026 stood at $46.9 million (up 47.99% YoY), and the FY2025 full-year result was $42.2 million, up 59.81% from the prior year.
• Revenue retreated to $12.3 million in Q1 2026, from $12.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $91.5 million in Q4 2023 to a low of $2.3 million in Q1 2024.
• A 5-year average of $32.3 million and a median of $12.7 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 92.88% in 2024 and soared 229.25% in 2025, its largest moves.
• Tracing CHRS's Revenue over 5 years: stood at $45.4 million in 2022, then jumped by 101.81% to $91.5 million in 2023, then slumped by 91.55% to $7.7 million in 2024, then surged by 64.85% to $12.7 million in 2025, then fell by 3.44% to $12.3 million in 2026.
• Business Quant data shows CHRS's Revenue at $12.3 million in Q1 2026, $12.7 million in Q4 2025, and $11.6 million in Q3 2025.